Abstract：Objective To investigate the prognosis of childhood T-lymphoblastic lymphoma (T-LBL) treated with acute lymphoblastic leukemia (ALL) regimen and related influencing factors. Methods A retrospective analysis was performed for the prognostic characteristics of 29 children with T-LBL who were treated with ALL regimen (ALL-2009 or CCCG-ALL-2015 regimen) from May 2010 to May 2022. Results The 29 children with T-LBL had a 5-year overall survival (OS) rate of 84%±7% and an event-free survival (EFS) rate of 81%±8%. The children with B systemic symptoms (unexplained fever >38°C for more than 3 days; night sweats; weight loss >10% within 6 months) at initial diagnosis had a lower 5-year EFS rate compared to the children without B symptoms (P<0.05). The children with platelet count >400×109/L and involvement of both mediastinum and lymph nodes at initial diagnosis had lower 5-year OS rates (P<0.05). There were no significant differences in 5-year OS and EFS rates between the children treated with CCCG-ALL-2015 regimen and those treated with ALL-2009 regimen (P>0.05). Compared with the ALL-2009 regimen, the CCCG-ALL-2015 regimen reduced the frequency of high-dose methotrexate chemotherapy and the incidence rate of severe infections (P<0.05). Conclusions The ALL regimen is safe and effective in children with T-LBL. Children with B systemic symptoms, platelet count >400×109/L, and involvement of both mediastinum and lymph nodes at initial diagnosis tend to have a poor prognosis. Reduction in the frequency of high-dose methotrexate chemotherapy can reduce the incidence rate of severe infections, but it does not affect prognosis.
HOU Shu-Min,SHAO Jing-Bo,LI Hong et al. Prognostic analysis of childhood T-lymphoblastic lymphoma treated with leukemia regimen[J]. CJCP, 2024, 26(5): 469-475.
Burkhardt B, Hermiston ML. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities[J]. Br J Haematol, 2019, 185(6): 1158-1170. PMID: 30809797. DOI: 10.1111/bjh.15793.
Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report[J]. Blood, 2000, 95(2): 416-421. PMID: 10627444.
Si Lim SJ, Ford JB, Hermiston ML. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults[J]. Blood, 2023, 141(25): 3019-3030. PMID: 37018730. DOI: 10.1182/blood.2022016503.
Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting[J]. J Clin Oncol, 1989, 7(11): 1630-1636. PMID: 2809679. DOI: 10.1200/JCO.1989.7.11.1630.
10 U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE): version 5.0[Z]. (2017-11-27)[2023-03-01]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
Dymicka-Piekarska V, Koper-Lenkiewicz OM, Zińczuk J, et al. Inflammatory cell-associated tumors. Not only macrophages (TAMs), fibroblasts (TAFs) and neutrophils (TANs) can infiltrate the tumor microenvironment. The unique role of tumor associated platelets (TAPs)[J]. Cancer Immunol Immunother, 2021, 70(6): 1497-1510. PMID: 33146401. PMCID: PMC8139882. DOI: 10.1007/s00262-020-02758-7.
Burkhardt B, Reiter A, Landmann E, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster group[J]. J Clin Oncol, 2009, 27(20): 3363-3369. PMID: 19433688. DOI: 10.1200/JCO.2008.19.3367.
22 Winter SS, Devidas M, Chen S, et al. Capizzi-style methotrexate with pegasparagase (C-MTX) is superior to high-dose methotrexate (HDMTX) in T-lineage acute lymphoblastic leukemia (T-ALL): results from Children's Oncology Group (COG) AALL0434[J]. Blood, 2015, 126(23): 794. DOI: 10.1182/blood.V126.23.794.794.
